Demand for fertility care has never been higher. Rising maternal age, changing family structures, and increased awareness of reproductive medicine are driving growth in the global fertility market. Yet despite this demand, access to fertility treatment remains limited for millions of people worldwide.
In many countries, patients face long waiting lists, restrictive and limiting regulations, financial barriers, and limited clinical capacity. These constraints mean that even as the fertility sector grows, access to care often fails to keep pace.
Addressing this challenge requires rethinking how fertility care is delivered, financed, and regulated.
A growing gap between demand and access?
Within fertility and reproductive medicine, there are several structural barriers making access for people particularly difficult.
1. Regulatory restrictions limit treatment availability
Fertility treatment is a highly regulated area of medicine. Laws governing assisted reproduction vary significantly across countries and even jurisdictions within same countries that may restrict:
– access based on marital/civil status, sexual orientation, or age
– donor gamete availability or legal compliance to use gamete donors
– embryo research and genetic testing
– cross-border reproductive care
While many regulations are designed to ensure safety and ethical standards, they also limit treatment access for certain patient groups or reduce the availability of donor gametes and fertility services, whereby the result might be exact opposite leading people into choosing unsafe solutions.
In addition, many people travel internationally to access treatments that are unavailable or restricted in their home countries also known as fertility tourism or CBRC (cross-border reproductive care).
2. Financial barriers remain one of the largest obstacles
Unlike many other medical services, fertility treatment is frequently either not at all or not fully reimbursed by national healthcare systems or insurers. IVF cycles, fertility preservation, and donor programs often involve significant out-of-pocket costs, creating substantial barriers to treatment.
Financial barriers are a well-recognized driver of healthcare inequality, as individuals without sufficient resources may delay or forgo treatment altogether i.e. having the result that access to parenthood is increasingly tied to financial capability.
3. Capacity constraints across fertility clinics
Even in countries where treatment is permitted and affordable, access is constrained by limited clinical capacity illustrated by long waiting times. Fertility clinics require highly specialised infrastructure, including IVF laboratories, advanced equipment, and regulatory compliance frameworks. Expanding this capacity takes time and significant investment.
In addition, one of the most critical and often overlooked constraints is the global shortage of experienced fertility specialists and senior embryologists. Reproductive medicine requires years of specialised training, and embryology expertise is particularly difficult to scale quickly. The limited availability of experienced professionals means that even where demand and infrastructure exist, clinics may struggle to expand treatment capacity.
4. Fragmentation across the fertility ecosystem
The fertility sector is also highly fragmented. Patients may interact with multiple providers across the fertility value chain:
– fertility clinics
– diagnostic laboratories
– gamete banks
– fertility technology providers
– genetic testing companies
Without coordination across these actors, treatment pathways can become complex and inefficient, further slowing patient access.
Rethinking fertility care delivery
Addressing the access challenge will require innovation across several dimensions of the fertility ecosystem. Potential solutions might include:
Leveraging technology
– Digital patient pathways and remote consultations
– AI-supported laboratory processes and clinical decision tools
Revisiting regulatory frameworks
– Updating legislation to reflect evolving medical practice and patient needs with higher acceptance of new family forms
Improving financing models
– Better public financial- or insurance coverage
– Employer-sponsored fertility benefits
– Public-private healthcare partnerships
Developing the fertility workforce
– Training programs for embryologists and fertility specialists
– International knowledge transfer and education
Expanding clinical capacity
– Investment in new fertility clinics and laboratory infrastructure
– Scaling networks of IVF centers
A sector in a phase of structural transformation
The fertility sector is positioned at the intersection of medicine, technology, policy, and societal changes. Demand for treatment will continue to rise primarily due to age-induced infertility as well as new family form of single females and same-sex couples, but without targeted efforts to address regulatory, financial, and workforce barriers, access to fertility care will remain uneven.
For policymakers, healthcare providers, and investors alike, the challenge is clear: expand access while maintaining quality, safety, and ethical standards. Solving the fertility access challenge will require not just expanding capacity but fundamentally rethinking how fertility care is delivered and supported across the healthcare system.